Comparative mucosal immunogenicity of HIV gp41 membrane-proximal external region (MPER) containing single and multiple repeats of ELDKWA sequence with defensin peptides

Immunobiology

Volumn 219, Issue 4, 2014, Pages 292-301

  Mohan, Teena ^a   Verma, Priyanka ^a   Rao, D N ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Defensins; Gp41; HIV; IgG IgA antibodies; MPER; Neutralization

Indexed keywords

BETA DEFENSIN; GLYCOPROTEIN GP 41; GLYCOPROTEIN GP 41 GP41MEMBRANE PROXIMAL EXTERNAL REGION; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; IMMUNOGLOBULIN G2B ANTIBODY; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; BLOCKING ANTIBODY; DEFENSIN; EPITOPE; GP41 PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; LIPOSOME; PEPTIDE; VIRUS ANTIBODY;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; CARBOXY TERMINAL SEQUENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SYNTHESIS; ELDKWA SEQUENCE; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IN VITRO STUDY; INBRED MOUSE STRAIN; LIPOSOMAL DELIVERY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; OUTBRED MOUSE STRAIN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN CONFORMATION; STRUCTURE ACTIVITY RELATION; TH1 CELL; TH2 CELL; VACCINE PRODUCTION; VIRAL CLEARANCE; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; METABOLISM; PROTEIN MOTIF;

ADJUVANTS, IMMUNOLOGIC; AIDS VACCINES; AMINO ACID MOTIFS; ANIMALS; ANTIBODIES, BLOCKING; ANTIBODIES, VIRAL; DEFENSINS; DISEASE MODELS, ANIMAL; EPITOPES, B-LYMPHOCYTE; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; LIPOSOMES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PEPTIDES;

EID: 84895444917     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2013.11.001     Document Type: Article

References (50)

1. Agrawal L., Haq W., Hanson C.V., Rao D.N. Generating neutralizing antibodies, Th1 response and MHC non-restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity. J. Immune Based Ther. Vaccines 2003, 1:282-293.
2. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
3. Beenhouwer D.O., May R.J., Valadon P., Scharff M.D. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library. J. Immunol. 2002, 169:6992-6999.
4. Cafaro A., Macchia I., Maggiorella M.T., et al. Innovative approaches to develop prophylactic and therapeutic vaccines against HIV/AIDS. Adv. Exp. Med. Biol. 2009, 655:189-242.
5. Coeffier E., Clement J.M., Cussac V., Khodaei-Boorane N., Jehanno M., et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 2000, 19:684-693.
6. Cohen J. Clinical research. A setback and an advance on the AIDS vaccine front. Science 2003, 300:28-29.
7. Cortes-Perez N.G., et al. Influence of the route of immunization and the nature of the bacterial vector on immunogenicity of mucosal vaccines based on lactic acid bacteria. Vaccine 2007, 25:6581-6588.
8. Curtis P.B., Gregory D.S., Liao H.X., Haynes B.F., Staats H.F. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J. Virol. 2002, 76:517-524.
9. Eckhart L., Raffelsberger W., Ferko B., Klima A., Purtscher M., et al. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. J. Gen. Virol. 1996, 77:2001-2008.
10. Fukuyama S., et al. Cutting edge: uniqueness of lymphoid chemokine requirement for the initiation and maturation of nasopharynx-associated lymphoid tissue organogenesis. J. Immunol. 2006, 177:4276-4280.
11. Gabuzda D.H., Lever A., Terwilliger E., Sodroski J. Effects of deletions in the cytoplasmic domain on biological functions of human immunodeficiency virus type 1 envelope glycoproteins. J. Virol. 1992, 66:3306-3315.
12. Gallo R.C., Sarin P.S., Gelmann E.P., Robert-Guroff M., Richardson E., et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983, 220:865-867.
13. Garrity R.R., Rimmelzwaan A., Minassian W.P., Tsai G. Refocusing neutralizing antibody response by targeted dampening of an immunodominant epitope. J. Immunol. 1997, 159:279-289.
14. Graham B.S., McElrath M.J., Connor R.I., Schwartz D.H., Gorse G.J., et al. Analysis of intercurrent human immunodeficiency virus type 1 infections in phase I and II trials of candidate AIDS vaccines. AIDS Vaccine Evaluation Group, and the Correlates of HIV Immune Protection Group. J. Infect. Dis. 1998, 177:310-319.
15. Hallenberger S., Bosch V., Angliker H., Shaw E., Klenk H.D., Garten W. Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160. Nature 1992, 360:358-361.
16. Ba-L. J. Virol. 2010, 84:1302-1313.
17. Hinz A., Schoehn G., Quendler H., Hulsik D.L., Stiegler G., et al. Characterization of a trimeric MPER containing HIV-1 gp41 antigen. Virology 2009, 390:221-227.
18. Ho J., Uger R.A., Zwick M.B., Luscher M.A., Barber B.H., et al. Conformational constraints imposed on a pan-neutralizing HIV-1 antibody epitope result in increased antigenicity but not neutralizing response. Vaccine 2005, 23:1559-1573.
19. Killian J.A., Nyholm T.K. Peptides in lipid bilayers: the power of simple models. Curr. Opin. Struct. Biol. 2006, 16:473-479.
20. Kiyono H., Fukuyama S. NALT- versus Peyer's-patch-mediated mucosal immunity. Nat. Rev. Immunol. 2004, 4:699-710.
21. Lenz O., Dittmar M.T., Wagner A., Ferko B., Weissenhorn W., et al. Trimeric membrane-anchored gp41 inhibits HIV membrane fusion. J. Biol. Chem. 2005, 280:4095-4101.
22. Liang X., Munshi S., Shendure J., Mark G., Davies M.E., et al. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine 1999, 17:2862-2872.
23. Lu M., Kim P.S. A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J. Biomol. Struct. Dyn. 1997, 15:465-471.
24. Manocha M., Pal P.C., Chitralekha K.T., Thomas B., Rao D.N., et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLGA microparticles in combination with UlexEuropaeus-I lectin as M cell target. Vaccine 2005, 23:5599-5617.
25. Mohan T., Mitra D., Rao D.N. Nasal delivery of PLG microparticle encapsulated defensin peptides adjuvanted gp41 antigen confers strong and long-lasting immunoprotective response against HIV-1. Immunol. Res. 2013, (Epub ahead of print).
26. Mohan T., Sharma C., Bhat A.A., Rao D.N. Modulation of HIV peptide antigen specific cellular immune response by synthetic α- and β-defensin peptides. Vaccine 2013, 31(13):1707-1716.
27. Montero M., van Houten N.E., Wang X., Scott J.K. The membrane proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 2008, 72:54-84.
28. Mullins D.W., et al. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J. Exp. Med. 2003, 198:1023-1034.
29. Oppenheim J.J., Biragyn A., Kwak L.W., Yang D. Roles of antimicrobial peptides such as defensins in innate and adaptive immunity. Ann. Rheum. Dis. 2003, 62:ii17-ii21. 10.1136/ard.62.suppl_2.ii17.
30. Phogat S., Svehla K., Tang M., Spadaccini A., Muller J., et al. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles. Virology 2008, 373:72-84.
31. Pitisuttithum P., Gilbert P., Gurwith M., Heyward W., Martin M., et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 2006, 194:1661-1671.
32. Pun P.B., Bhat A.A., Mohan T., Kulkarni S., Paranjape R., Rao D.N. Intranasal administration of peptide antigens of HIV with mucosal adjuvant CpG ODN coentrapped in microparticles enhances the mucosal and systemic immune responses. Int. Immunopharmacol. 2009, 9(4):468-477.
33. Raj P.A., Antonyraj K.J., Karunakaran T. Large-scale synthesis and functional elements for the antimicrobial activity of defensins. Biochem. J. 2000, 347:633-641.
34. Salzwedel K., West J.T., Hunter E. A conserved tryptophan-rich motif in the membrane-proximal region of the human immunodeficiency virus type 1 gp41 ectodomain is important for Env-mediated fusion and virus infectivity. J. Virol. 1999, 73:2469-2480.
35. Sherry M.O., Rudolph D.L., Wang W., Cole A.M., Lehrer R.I. RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res. Hum. Retroviruses 2004, 20:1157-1165.
36. + T-cell responses in mucosal tissues of macaques. J. Virol. 2002, 76:11659-11676.
37. Stopar D., Spruijt R.B., Hemminga M.A. Anchoring mechanisms of membrane-associated M13 major coat protein. Chem. Phys. Lipids 2006, 141:83-93.
38. Tani K., Murphy W.J., Chertov O., Salcedo R., Koh C.Y. Defensins act as potent adjuvant that promotes cellular and humoral immune responses in mice to a lymphoma idiotype and carrier antigen. Int. Immunol. 2000, 12:691-700.
39. Tani K., Murphy W.J., Chertov O., Oppenheim J.J., Wang J.M. The neutrophil granule protein cathepsin G activates murine T lymphocytes and upregulates antigen-specific Ig production in mice. Biochem. Biophys. Res. Commun. 2001, 282:971-976.
40. Teixeira C., Gomes J.R., Gomes P., Maurel F., Barbault F. Viral surface glycoproteins, gp120 and gp41, as potential drug targets against HIV-1: brief overview one quarter of a century past the approval of zidovudine, the first anti-retroviral drug. Eur. J. Med. Chem. 2011, 46:979-992.
41. Thakar M.R., Kumar B.K., Mhahjan B.A., Mehendale S.M., Paranjape R.S. Extensive cross-reactive neutralizing antibody response in Indian patients with limited genetic diversity of HIV. Virology 2007, 359:295-301.
42. Tripathi V., Chitralekha K.T., Bakshi A.R., Rao D.N., et al. Inducing systemic and mucosal immune responses to B-T construct of F1 antigen of Yersinia pestis in microsphere delivery. Vaccine 2006, 24:3279-3289.
43. Vajdy M., Singh M. Intranasal delivery of vaccines against HIV. Expert Opin. Drug Deliv. 2006, 3:247-259.
44. Vishwanathan S.A., Hunter E. Importance of the membrane-perturbing properties of the membrane-proximal external region of human immunodeficiency virus type 1 gp41 to viral fusion. J. Virol. 2008, 82:5118-5126.
45. Wyatt R., Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888.
46. Yang D., Biragyn A., Kwak L.W., Oppenheim J.J. Mammalian defensins in immunity: more than just microbicidal. Trends Immunol. 2002, 23:291-296.
47. Yang D., Biragyn A., Hoover D.M., Lubkowski J., Oppenheim J.J. Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu. Rev. Immunol. 2004, 22:181-215.
48. Ye L., Wen Z., Dong K., Wang X., Bu Z., et al. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA/gp41 chimeric protein-based DNA and VLP vaccines. PLoS ONE 2011, 6:231-255.
49. Zhou Q., Hidajat R., Peng B., et al. Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV (mac251). Vaccine 2007, 25:8021-8035.
50. Zwick M.B., Jensen R., Church S., Wang M., Stiegler G., et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J. Virol. 2005, 79:1252-1261.